PLL developed an expertise in molecule enhancement and stability using poly-lysine technology as drug delivery enabler.
Due to the antibody’s expertise and molecule enhancement, PLL was able to develop their own treatment with companion diagnostic against one of the main public health problems which are neurodegenerative diseases with a first proof of concept target in ALS (Amyotrophic lateral sclerosis).
The company was launched by new investors through their holding company HFT and since January 2021 PLL-THERAPEUTICS was created to hold our assets ( patents R&D work…) and focus on commercializing the R&D pipe-line in the field of neurodegenerative diagnostics and therapies to commercial phase.
More and more the Gut is highlighted in many diseases as playing a key role in Parkinson or ALS by being the open gate for many components as bacteria, fungal element, lipopolysaccharides (LPS), toxins and chemicals to move in the blood and in the brain which can have a role in the development of the disease and in its chronicity....